Skip to main content
Erschienen in: Cancer Causes & Control 5/2012

01.05.2012 | Original paper

Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden

verfasst von: Bo Attner, Mona Landin-Olsson, Thor Lithman, Dennis Noreen, Håkan Olsson

Erschienen in: Cancer Causes & Control | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

To study how the incidence of cancer is related to diabetes, obesity or abnormal blood lipids.

Methods

Diagnosis of diabetes, obesity or abnormal blood lipids was studied 0-10 years prior to the diagnosis of cancer in 19,756 cases of cancer and in 147,324 controls matched regarding age, sex and domicile.

Results

Diabetes was significantly more common prior to diagnosis in patients with liver, pancreatic, colon and urinary tract/bladder cancer and in patients with breast cancer diagnosed with diabetes 0–4 years prior to the cancer diagnosis. A lower risk of diabetes was seen in patients with prostate carcinoma among individuals with diabetes diagnosed 5–10 years prior to the cancer diagnosis. The findings remained after adjusting for obesity and high blood lipids. Obesity was significantly more common in patients with endometrial, colon and kidney cancer and with breast cancer above the age of 60 years in those where obesity was diagnosed close to the diagnosis of cancer. High blood lipids were significantly more common in patients with ovarian cancer and less common in patients with breast cancer.

Conclusions

The study confirms some previous findings concerning comorbidity and cancer and highlights some new ones.
Literatur
1.
Zurück zum Zitat LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S (2008) Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes 116(Suppl 1):S4–S6PubMedCrossRef LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S (2008) Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes 116(Suppl 1):S4–S6PubMedCrossRef
2.
Zurück zum Zitat Mori M, Saitoh S, Takagi S, Obara F, Ohnishi H, Akasaka H et al (2000) A Review of Cohort Studies on the Association Between History of Diabetes Mellitus and Occurrence of Cancer. Asian Pac J Cancer Prev 1(4):269–276PubMed Mori M, Saitoh S, Takagi S, Obara F, Ohnishi H, Akasaka H et al (2000) A Review of Cohort Studies on the Association Between History of Diabetes Mellitus and Occurrence of Cancer. Asian Pac J Cancer Prev 1(4):269–276PubMed
3.
Zurück zum Zitat Hjartaker A, Langseth H, Weiderpass E (2008) Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol 630:72–93PubMedCrossRef Hjartaker A, Langseth H, Weiderpass E (2008) Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol 630:72–93PubMedCrossRef
4.
Zurück zum Zitat Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33(7):1674–1685 [Epub 2010/07/01]PubMedCrossRef Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33(7):1674–1685 [Epub 2010/07/01]PubMedCrossRef
5.
Zurück zum Zitat Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16(4):1103–1123 [Epub 2009/07/22]PubMedCrossRef Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16(4):1103–1123 [Epub 2009/07/22]PubMedCrossRef
6.
Zurück zum Zitat Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364(9):829–841 [Epub 2011/03/04]PubMedCrossRef Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364(9):829–841 [Epub 2011/03/04]PubMedCrossRef
7.
Zurück zum Zitat Kritchevsky S (1992) Serum cholesterol and cancer risk: an epidemiologic perspective. Annu Rev Nutr 12:391–416PubMedCrossRef Kritchevsky S (1992) Serum cholesterol and cancer risk: an epidemiologic perspective. Annu Rev Nutr 12:391–416PubMedCrossRef
8.
Zurück zum Zitat Michalaki V, Koutroulis G, Syrigos K, Piperi C, Kalofoutis A (2005) Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol Cell Biochem 268(1–2):19–24PubMedCrossRef Michalaki V, Koutroulis G, Syrigos K, Piperi C, Kalofoutis A (2005) Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol Cell Biochem 268(1–2):19–24PubMedCrossRef
9.
Zurück zum Zitat Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, Virtamo J et al (2009) Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 18(11):2814–2821 [Epub 2009/11/06]PubMedCrossRef Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, Virtamo J et al (2009) Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 18(11):2814–2821 [Epub 2009/11/06]PubMedCrossRef
10.
Zurück zum Zitat Jacobs EJ, Gapstur SM (2009) Cholesterol and cancer: answers and new questions. Cancer Epidemiol Biomarkers Prev 18(11):2805–2806 [Epub 2009/11/06]PubMedCrossRef Jacobs EJ, Gapstur SM (2009) Cholesterol and cancer: answers and new questions. Cancer Epidemiol Biomarkers Prev 18(11):2805–2806 [Epub 2009/11/06]PubMedCrossRef
11.
Zurück zum Zitat Drummond MF, Botten G, Hakkinen U, Pedersen KM (2006) Assessing the quality of Swedish health economics research. Scand J Public Health 34(6):566–570 [Epub 2006/11/3]PubMedCrossRef Drummond MF, Botten G, Hakkinen U, Pedersen KM (2006) Assessing the quality of Swedish health economics research. Scand J Public Health 34(6):566–570 [Epub 2006/11/3]PubMedCrossRef
12.
Zurück zum Zitat Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48(1):27–33 [Epub 2008/09/04]PubMedCrossRef Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48(1):27–33 [Epub 2008/09/04]PubMedCrossRef
13.
Zurück zum Zitat The National Board of Health and Welfare (2008) Cancer incidence in Sweden 2007. Health Dis 11:1–117 The National Board of Health and Welfare (2008) Cancer incidence in Sweden 2007. Health Dis 11:1–117
14.
Zurück zum Zitat Huxley R, Ansary-Moghaddam A, de Gonzalez AB, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92(11):2076–2083 [Epub 2005/05/12]PubMedCrossRef Huxley R, Ansary-Moghaddam A, de Gonzalez AB, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92(11):2076–2083 [Epub 2005/05/12]PubMedCrossRef
15.
Zurück zum Zitat Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT (2010) Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control [Epub 2010/11/26] Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT (2010) Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control [Epub 2010/11/26]
16.
Zurück zum Zitat Genkinger JM, Spiegelman D, Anderson KE, Bernstein L, van den Brandt PA, Calle EE et al (2010) A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer 129(7):1708–1717 [Epub 2010/11/26]CrossRef Genkinger JM, Spiegelman D, Anderson KE, Bernstein L, van den Brandt PA, Calle EE et al (2010) A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer 129(7):1708–1717 [Epub 2010/11/26]CrossRef
17.
Zurück zum Zitat Colhoun HM (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52(9):1755–1765 [Epub 2009/07/16]PubMedCrossRef Colhoun HM (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52(9):1755–1765 [Epub 2009/07/16]PubMedCrossRef
18.
Zurück zum Zitat Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52(9):1732–1744 [Epub 2009/07/01]PubMedCrossRef Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52(9):1732–1744 [Epub 2009/07/01]PubMedCrossRef
19.
Zurück zum Zitat Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 52(9):1745–1754 [Epub 2009/07/10]PubMedCrossRef Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 52(9):1745–1754 [Epub 2009/07/10]PubMedCrossRef
20.
Zurück zum Zitat Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C et al (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33(9):1997–2003 [Epub 2010/06/17]PubMedCrossRef Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C et al (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33(9):1997–2003 [Epub 2010/06/17]PubMedCrossRef
21.
Zurück zum Zitat Becker S, Dossus L, Kaaks R (2009) Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 115(2):86–96PubMedCrossRef Becker S, Dossus L, Kaaks R (2009) Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 115(2):86–96PubMedCrossRef
22.
Zurück zum Zitat Schiel R, Beltschikow W, Steiner T, Stein G (2006) Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol 28(3):169–175PubMedCrossRef Schiel R, Beltschikow W, Steiner T, Stein G (2006) Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol 28(3):169–175PubMedCrossRef
23.
Zurück zum Zitat Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503):1304–1305PubMedCrossRef Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503):1304–1305PubMedCrossRef
24.
Zurück zum Zitat Smith U, Gale EA (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52(9):1699–1708 [Epub 2009/07/15]PubMedCrossRef Smith U, Gale EA (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52(9):1699–1708 [Epub 2009/07/15]PubMedCrossRef
25.
Zurück zum Zitat Siekmeier R, Scheuch G (2008) Inhaled insulin—does it become reality? J Physiol Pharmacol 59(Suppl 6):81–113PubMed Siekmeier R, Scheuch G (2008) Inhaled insulin—does it become reality? J Physiol Pharmacol 59(Suppl 6):81–113PubMed
26.
Zurück zum Zitat Bonovas S, Filioussi K, Tsantes A (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47(6):1071–1078PubMedCrossRef Bonovas S, Filioussi K, Tsantes A (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47(6):1071–1078PubMedCrossRef
27.
Zurück zum Zitat Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(11):2056–2062 [Epub 2006/11/23]PubMedCrossRef Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(11):2056–2062 [Epub 2006/11/23]PubMedCrossRef
28.
Zurück zum Zitat Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA (2009) Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 169(8):937–945PubMedCrossRef Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA (2009) Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 169(8):937–945PubMedCrossRef
29.
Zurück zum Zitat Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124(6):1398–1403PubMedCrossRef Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124(6):1398–1403PubMedCrossRef
30.
Zurück zum Zitat Frayling TM, Colhoun H, Florez JC (2008) A genetic link between type 2 diabetes and prostate cancer. Diabetologia 51(10):1757–1760PubMedCrossRef Frayling TM, Colhoun H, Florez JC (2008) A genetic link between type 2 diabetes and prostate cancer. Diabetologia 51(10):1757–1760PubMedCrossRef
31.
Zurück zum Zitat Chu DI, Freedland SJ (2010) Metabolic risk factors in prostate cancer. Cancer [Epub 2010/12/01] Chu DI, Freedland SJ (2010) Metabolic risk factors in prostate cancer. Cancer [Epub 2010/12/01]
32.
Zurück zum Zitat Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578PubMedCrossRef Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578PubMedCrossRef
33.
Zurück zum Zitat Giovannucci E, Michaud D (2007) The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132(6):2208–2225 [Epub 2007/05/15]PubMedCrossRef Giovannucci E, Michaud D (2007) The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132(6):2208–2225 [Epub 2007/05/15]PubMedCrossRef
34.
Zurück zum Zitat Ning Y, Wang L, Giovannucci EL (2009) A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev 11(1):19–30 [Epub 2009/06/23]PubMedCrossRef Ning Y, Wang L, Giovannucci EL (2009) A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev 11(1):19–30 [Epub 2009/06/23]PubMedCrossRef
35.
Zurück zum Zitat Tornberg SA, Holm LE, Carstensen JM (1988) Breast cancer risk in relation to serum cholesterol, serum beta-lipoprotein, height, weight, and blood pressure. Acta Oncol 27(1):31–37 [Epub 1988/01/01]PubMedCrossRef Tornberg SA, Holm LE, Carstensen JM (1988) Breast cancer risk in relation to serum cholesterol, serum beta-lipoprotein, height, weight, and blood pressure. Acta Oncol 27(1):31–37 [Epub 1988/01/01]PubMedCrossRef
36.
Zurück zum Zitat Vatten LJ, Foss OP (1990) Total serum cholesterol and triglycerides and risk of breast cancer: a prospective study of 24,329 Norwegian women. Cancer Res 50(8):2341–2346 [Epub 1990/04/15]PubMed Vatten LJ, Foss OP (1990) Total serum cholesterol and triglycerides and risk of breast cancer: a prospective study of 24,329 Norwegian women. Cancer Res 50(8):2341–2346 [Epub 1990/04/15]PubMed
37.
Zurück zum Zitat Helzlsouer KJ, Alberg AJ, Norkus EP, Morris JS, Hoffman SC, Comstock GW (1996) Prospective study of serum micronutrients and ovarian cancer. J Natl Cancer Inst 88(1):32–37 [Epub 1996/01/03]PubMedCrossRef Helzlsouer KJ, Alberg AJ, Norkus EP, Morris JS, Hoffman SC, Comstock GW (1996) Prospective study of serum micronutrients and ovarian cancer. J Natl Cancer Inst 88(1):32–37 [Epub 1996/01/03]PubMedCrossRef
38.
Zurück zum Zitat Bjørge T, Lukanova A, Tretli S, Manjer J, Ulmer H, Stocks T et al (2011) Metabolic risk factors and ovarian cancer in the Metabolic Syndrome and Cancer project. Int J Epidemiol 40(6):1667–1677 [Epub 2011/10/11]PubMedCrossRef Bjørge T, Lukanova A, Tretli S, Manjer J, Ulmer H, Stocks T et al (2011) Metabolic risk factors and ovarian cancer in the Metabolic Syndrome and Cancer project. Int J Epidemiol 40(6):1667–1677 [Epub 2011/10/11]PubMedCrossRef
Metadaten
Titel
Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden
verfasst von
Bo Attner
Mona Landin-Olsson
Thor Lithman
Dennis Noreen
Håkan Olsson
Publikationsdatum
01.05.2012
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 5/2012
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-9946-5

Weitere Artikel der Ausgabe 5/2012

Cancer Causes & Control 5/2012 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.